All In Biotech

Drug Trial Radar · NCT06279793

Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients

Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients: a Phase II Multicenter Trial - A Randomized, Placebo-controlled Trial -

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Feb 15, 2024

Primary completion

Mar 2030

Study completion Sep 2030

Sponsor

Sponsor type
Industry
Collaborators
University Hospital, Bonn; University Hospital Muenster; University Hospital Goettingen; Charite University, Berlin, Germany; Wuerzburg University Hospital; Johannes Gutenberg University Mainz; University Hospital Augsburg; Universitätsklinikum Hamburg-Eppendorf; University Medical Center Rostock; University Hospital Schleswig-Holstein; Robert Bosch-Krankenhaus Stuttgart
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy. A total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil/kg body weight (BW) + standard of care versus same volume of placebo (NaCl) + standard of care.

Conditions

  • Intensive Care Unit
  • Coronary Artery Bypass Grafting (CABG)
  • High Risk Patients
  • Cardiopulmonary Bypass
  • Elective Cardiac Surgery
  • Valvular Heart Surgery
  • Multiple Valve Surgeries
  • Combined Cardiac Procedures
  • Aortic Surgical Procedures
  • Adult Patients ≥ 18 Years
  • Combined Valve and CABG
  • Combined Cardiac and Aortic Surgical Procedures

Interventions

  • Fish OilDrug

    Omegaven® is a 10% fish oil emulsion with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids. Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose. Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL). Timeframe: Day -1: 0.20 g fish oil/kg BW/d (the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion); intraoperative day 0: no dose; postoperative day 0: 0.20 g fish oil/kg BW/d; postoperative days 1 to max. 7): 0.20 g fish oil/kg BW/d

  • Intravenous 0.9% Sodium ChlorideDrug

    Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d) provided at the same timepoints as the intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Atrial fibrillationTime frame: Postoperative days 0-7

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospital Augsburg

    Augsburg, Germany · Recruiting

  • Charité Universitätsmedizin Berlin

    Berlin, Germany · Recruiting

  • University of Bonn

    Bonn, Germany · Recruiting

  • University Hospital Goettingen

    Göttingen, Germany · Recruiting

  • University Hospital Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • University Medical Center Schleswig-Holstein

    Kiel, Germany · Recruiting

  • University Hospital Mainz

    Mainz, Germany · Recruiting

  • University Hospital Muenster

    Münster, Germany · Recruiting

  • University Medical Center Rostock

    Rostock, Germany · Not yet recruiting

  • Robert Bosch Medical Center

    Stuttgart, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.